CRISPR Therapeutics AG
Last updated September 27, 2026
Organization details
- Legal name
- CRISPR Therapeutics AG
- Ownership
- Public
- Status
- Active
- Headquarters country
- Switzerland
- Ticker symbol
- CRSP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001674416
Board of directors
- Since 2023
-
Briggs Morrison · DirectorSince 2025
-
Christian Rommel · DirectorSince 2024
-
Douglas A. Treco · DirectorSince 2023
-
Harold Edward Fleming · DirectorSince 2023
-
John Greene · DirectorSince 2023
-
Katherine A. High · DirectorSince 2023
-
Maria Fardis · DirectorSince 2023
-
Samarth Kulkarni · Director · Chief Executive OfficerSince 2023
-
Sandesh Mahatme · DirectorSince 2024
-
Simeon George · DirectorSince 2023
Chief executives
Samarth Kulkarni
· Chief Executive Officer
Dates unknown
Board connections
7 of this board's directors also sit on 15 other boards.
- via Ali Behbahani and Samarth Kulkarni
- via Ali Behbahani and Simeon George
- via Briggs Morrison
- via Ali Behbahani
- via Simeon George
- via Katherine A. High
- via Ali Behbahani
- via Ali Behbahani
- via Maria Fardis
- via Samarth Kulkarni
- via Harold Edward Fleming
- via Ali Behbahani
- via Briggs Morrison
- via Harold Edward Fleming
- via Briggs Morrison
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $18,273,667
- 28 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | KASINGER JAMES R. Officer (General Counsel and Secretary) | Option exercise | +10,400 | $13.62 | $141,648 |
| Sep 22, 2026 | KASINGER JAMES R. Officer (General Counsel and Secretary) | Open-market sale | −10,400 | $60.24 | $626,460 |
| Sep 17, 2026 | Ali Behbahani Director | Option exercise | +30,000 | $14.00 | $420,000 |
| Sep 17, 2026 | Ali Behbahani Director | Open-market sale | −13,679 | $57.09 | $780,935 |
| Aug 7, 2026 | Prasad Raju Officer (Chief Financial Officer) | Gift | −750 | — | — |
| May 29, 2026 | Patel Naimish Officer (Chief Medical Officer) | Open-market sale | −3,786 | $55.62 | $210,577 |
| May 28, 2026 | Patel Naimish Officer (Chief Medical Officer) | Option exercise | +10,000 | — | — |
| Mar 23, 2026 | KASINGER JAMES R. Officer (General Counsel and Secretary) | Open-market sale | −3,182 | $46.78 | $148,854 |
| Mar 23, 2026 | Samarth Kulkarni Director, Officer (Chief Executive Officer) | Open-market sale | −10,020 | $46.78 | $468,736 |
| Mar 23, 2026 | Prasad Raju Officer (Chief Financial Officer) | Open-market sale | −3,708 | $46.78 | $173,460 |
| Mar 20, 2026 | KASINGER JAMES R. Officer (General Counsel and Secretary) | Option exercise | +6,250 | — | — |
| Mar 20, 2026 | Samarth Kulkarni Director, Officer (Chief Executive Officer) | Option exercise | +19,687 | — | — |
| Mar 20, 2026 | Prasad Raju Officer (Chief Financial Officer) | Option exercise | +6,250 | — | — |
| Mar 16, 2026 | Patel Naimish Officer (Chief Medical Officer) | Open-market sale | −3,150 | $48.26 | $152,019 |
| Mar 16, 2026 | KASINGER JAMES R. Officer (General Counsel and Secretary) | Open-market sale | −3,450 | $48.26 | $166,497 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.